<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-95334" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Toxoplasmosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Madireddy </surname>
            <given-names>Sowmya</given-names>
          </name>
          <aff>Mamata Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mangat</surname>
            <given-names>Rupinder</given-names>
          </name>
          <aff>University of Rochester Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sowmya Madireddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rupinder Mangat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-95334.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Toxoplasmosis is an infection caused by the zoonotic parasite <italic toggle="yes">Toxoplasma gondii</italic>, an obligate intracellular protozoan. <italic toggle="yes">T gondii</italic> has a&#x000a0;global distribution, with cats being the definite hosts that shed oocysts with their feces into the environment. Although&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;is present worldwide,&#x000a0;it rarely causes clinically significant disease in&#x000a0;immunocompetent people, and those with primary infections&#x000a0;are usually&#x000a0;asymptomatic.&#x000a0;Some immunocompetent people, however, do develop acute disease, mainly with nonspecific systemic symptoms, central nervous system disease, or ocular disease&#x02014;typically posterior uveitis. Initial infections become latent and persist for life. Patients who have latent infection and then become immunocompromised due to various causes, including chemotherapy,&#x000a0; human immunodeficiency virus/acquired immunodeficiency syndrome, or organ transplantation, can develop reactivation of toxoplasmosis, which usually manifests as central nervous system ring-enhancing lesions.&#x000a0;</p>
        <p>Through this course, participants understand the pathogenesis, evaluation, and management of toxoplasmosis, focusing on recognizing and treating acute infections and reactivations. The course emphasizes the importance of an interprofessional team in managing toxoplasmosis, as collaboration between infectious disease specialists, neurologists, ophthalmologists, and other healthcare professionals is crucial for prompt diagnosis and effective treatment.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify acute and reactivated toxoplasmosis's clinical signs and symptoms, particularly in immunocompromised individuals.</p></list-item><list-item><p>Differentiate toxoplasmosis from other infections with similar presentations, especially in the central nervous system or ocular involvement cases.</p></list-item><list-item><p>Screen high-risk individuals for toxoplasmosis, such as those with human immunodeficiency virus/acquired immunodeficiency syndrome, undergoing chemotherapy, or post-transplant, for latent toxoplasmosis to prevent reactivation.</p></list-item><list-item><p>Develop effective communication and collaboration within the interprofessional team to enhance the care of those infected with toxoplasmosis&#x000a0;and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=95334&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=95334">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-95334.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Toxoplasmosis is a zoonotic infection&#x000a0;caused by <italic toggle="yes">Toxoplasma&#x000a0;</italic><italic toggle="yes">gondii</italic>, an obligate intracellular parasitic protozoan. <italic toggle="yes">T gondii</italic> can infect all warm-blooded vertebrates, including humans.&#x000a0;Domestic and wild felids are the definitive hosts, shedding unsporulated oocysts with their feces into the environment.<xref ref-type="bibr" rid="article-95334.r1">[1]</xref> Transmission of infection often occurs through ingesting tissue cysts via improperly cooked or raw meat or contaminated food or water.<xref ref-type="bibr" rid="article-95334.r1">[1]</xref>&#x000a0;Other routes of transmission include vertical transmission, causing miscarriage or congenital toxoplasmosis, and via transplantation, by&#x000a0;<italic toggle="yes">T gondii </italic>from either the host or donor organ.<xref ref-type="bibr" rid="article-95334.r2">[2]</xref></p>
        <p>Although&#x000a0;<italic toggle="yes">T gondii</italic> is present worldwide,&#x000a0;it rarely causes clinically significant disease in&#x000a0;immunocompetent people; those with primary infections&#x000a0;are usually&#x000a0;asymptomatic and may have subclinical infections.<xref ref-type="bibr" rid="article-95334.r3">[3]</xref>&#x000a0;Those who are immunocompetent can, however, develop acute toxoplasmosis that can manifest with nonspecific, constitutional symptoms, such as fever, malaise, and lymphadenopathy, as well as central nervous system pathology and&#x000a0;ocular disease, usually posterior uveitis.<xref ref-type="bibr" rid="article-95334.r3">[3]</xref>&#x000a0;The parasite is considered neurotropic and oculotropic. After the initial infection,&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;enters latency and persists for the host's life.&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;latent tissue cysts can reactivate in profoundly immunosuppressed people, including patients receiving chemotherapy, organ transplants, or those with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), causing severe disseminated infection. Reactivation can also occur during transplantation from reactivation from the host, from the donor organ, or primary infection.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref><xref ref-type="bibr" rid="article-95334.r5">[5]</xref></p>
        <p><italic toggle="yes">T gondii</italic> is a ubiquitous parasite that can cause severe disease in humans and even be fatal in patients with fulminant disease. Clinicians aren't highly aware of the presence of toxoplasmosis and its clinical presentation, especially in patients who are immunocompetent and have few symptoms. Thus, the disease burden is underestimated. A high index of suspicion is necessary, and appropriate evaluation, timely diagnosis, and treatment of patients with toxoplasmosis are essential.&#x000a0;</p>
      </sec>
      <sec id="article-95334.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">T gondii</italic> is an obligate intracellular parasite&#x000a0;that can infect all warm-blooded animals, including farm animals, birds, and humans.&#x000a0;<italic toggle="yes">T gondii</italic> has a complex life cycle, requiring a definitive host and an intermediate host to complete sexual and asexual cycles, respectively. The family Felidae members, including the domestic cat,&#x000a0;are the only known definitive hosts for this organism. Birds and terrestrial and aquatic mammals are the intermediate hosts.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref> Domesticated and wild cats can become infected by ingesting infected oocysts or tissue cysts from intermediate hosts or the environment.&#x000a0;Parasite transmission can occur by&#x000a0;ingesting&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;oocysts shed from felids, consuming&#x000a0;infected tissue from intermediate hosts, and congenital infection (vertical transmission via the placenta).<xref ref-type="bibr" rid="article-95334.r7">[7]</xref><xref ref-type="bibr" rid="article-95334.r8">[8]</xref></p>
        <p>There are 3 infectious stages of forms within the&#x000a0;<italic toggle="yes">T gondii</italic> life cycle: the tachyzoites, the bradyzoites, and the sporozoites.<xref ref-type="bibr" rid="article-95334.r9">[9]</xref>&#x000a0;When improperly cooked meat or food contaminated with cat feces is ingested, the outer cyst wall surrounding sporozoites and bradyzoites is proteolyzed by gastric juice in the alimentary canal.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref> These uncoated sporozoites and bradyzoites enter the gut epithelium and differentiate into tachyzoites. Tachyzoites are rapidly multiplying forms of <italic toggle="yes">T gondii</italic>.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref><xref ref-type="bibr" rid="article-95334.r9">[9]</xref>&#x000a0;Tachyzoites can penetrate any nucleated cell, including dendritic cells, monocytes, and neutrophils, resulting in dissemination. With the onset of the host immune response, these tachyzoites are repressed and eventually converted into slow-replicating forms termed bradyzoites. Bradyzoites form a thick cyst wall around them, forming a tissue cyst enclosing thousands of bradyzoites. These cysts remain in a dormant form in the immunocompetent host. However, they can get&#x000a0;reactivated when the host immune system is compromised.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref><xref ref-type="bibr" rid="article-95334.r9">[9]</xref>&#x000a0;</p>
        <p>The definite host, the felids, can become infected by ingesting sporulated oocysts or ingesting infected mammals or birds.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref><xref ref-type="bibr" rid="article-95334.r10">[10]</xref> The intermediate hosts, mammals, including humans, can become infected with&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;via various pathways, including ingesting infectious oocysts from the environment, eg, food, water, or plants contaminated with feline feces, or from eating tissue cysts or tachyzoites from undercooked, raw meat, or animal viscera, from blood products or organ or tissue transplantation, or ingestion of unpasteurized milk, from organs may contain cysts or tachyzoites, and congenitally through the maternal placenta.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref><xref ref-type="bibr" rid="article-95334.r10">[10]</xref></p>
        <p>Infected cats shed millions of unsporulated oocysts in the feces for about 1&#x000a0;to 3 weeks after&#x000a0;initial infection.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref> Oocysts take 1&#x000a0;to 5 days to sporulate and transform into infectious oocysts (sporozoites), which can remain infective in the environment for&#x000a0;up to a year. When intermediate hosts, such as birds or rodents, ingest these oocysts from plants, soil, or water, the oocysts become tachyzoites (rapid multiplication usually leading to acute infection), which embed in neural or muscle tissue and are then called bradyzoites.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref> Bradyzoites are slowly multiplying and are characteristic of chronic infection.<xref ref-type="bibr" rid="article-95334.r6">[6]</xref></p>
      </sec>
      <sec id="article-95334.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Toxoplasmosis is one of the most prevalent parasitic diseases that can infect terrestrial mammals, including humans. Toxoplasmosis is a true zoonotic disease since humans can acquire it from domestic, wild, companion, or farm animals. This disease exemplifies the One Health Principle, which is present in all aspects of the environment, including humans, soil, plants, water, and animals. Epidemiological data&#x000a0;reveal that humans acquire infections primarily by exposure to oocysts via ingestion of contaminated soil, water, or undercooked meat.<xref ref-type="bibr" rid="article-95334.r11">[11]</xref>. In the United States (US), toxoplasmosis was ranked second out of 5 foodborne pathogens with the highest public health burden, considering the high&#x000a0;cost of illness&#x000a0;and quality-adjusted life year.<xref ref-type="bibr" rid="article-95334.r12">[12]</xref></p>
        <p>Although infection is usually asymptomatic in immunocompetent people, it can still cause nonspecific symptoms, including fever, lymphadenopathy, and ocular disease, usually posterior uveitis.<xref ref-type="bibr" rid="article-95334.r3">[3]</xref>&#x000a0;Toxoplasmosis can rarely lead to myocarditis, hepatitis, and disseminated disease in a small number of immunocompetent people. In pregnant individuals, primary infection&#x000a0;leads to vertical transmission, transmission to the fetus, and congenital toxoplasmosis.</p>
        <p><italic toggle="yes">T gondii</italic> infection or reactivation in patients with profound immunosuppression can be life-threatening. These are patients with HIV/AIDS, solid organ transplants (SOT), hematopoietic stem cell transplantation (HSCT), and those receiving chemotherapy who develop toxoplasmosis either through primary infection&#x000a0;via contaminated food or a transplanted organ containing latent cysts.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref>&#x000a0;In patients with HIV/AIDS, risk factors affecting the prevalence of toxoplasmosis in these patients are similar to those of the general population. Still, they are at risk for developing opportunistic infection, more frequently cerebral toxoplasmosis, due to the reactivation of latent&#x000a0;<italic toggle="yes">T gondii,</italic>&#x000a0;notably when the cluster determinant 4 (CD4)</p>
        <p>lymphocyte count drops below 100 cells/&#x003bc;L.<xref ref-type="bibr" rid="article-95334.r13">[13]</xref></p>
        <p>Patients with&#x000a0;SOT and HSCT who have reactivated disease or primary disease can develop central nervous system disease, chorioretinitis, and disseminated infection.<xref ref-type="bibr" rid="article-95334.r5">[5]</xref><xref ref-type="bibr" rid="article-95334.r14">[14]</xref><xref ref-type="bibr" rid="article-95334.r15">[15]</xref>&#x000a0;Study results have shown that the seroprevalence for toxoplasmosis in patients with HSCT is variable and can reach up to 70%. Still, it is similar to age-matched healthy individuals in the same country.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref><xref ref-type="bibr" rid="article-95334.r5">[5]</xref>&#x000a0;In these patients, serological screening for immunoglobulin G, or use of the polymerase chain reaction to detect&#x000a0;<italic toggle="yes">T gondii,</italic>&#x000a0;can be undertaken to assess previous infection status and make decisions regarding prophylactic treatment. Lack of prophylaxis and profound immunosuppression in these patients can lead to poor outcomes.<xref ref-type="bibr" rid="article-95334.r16">[16]</xref>&#x000a0;</p>
        <p>Population studies have shown 3 predominant clonal lineages globally&#x02014;types I, II, and III&#x02014; found in specific geographical regions worldwide.&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;clonal lineage type II strains are predominantly found in humans and agricultural animals in Western Europe and North America.<xref ref-type="bibr" rid="article-95334.r11">[11]</xref>&#x000a0;Complete prevalence estimates that reflect the actual global burden of seropositivity of <italic toggle="yes">T gondii</italic> are lacking. There&#x000a0;are differences in surveillance&#x000a0;and reporting between countries, but very importantly, toxoplasmosis may&#x000a0;be underdiagnosed. Underdiagnosis may occur not only in those who are asymptomatic (either due to the presence of nonspecific symptoms, lack of resources, or low awareness of the disease and low index of suspicion by clinicians) but also in more severe cases of opportunistic infections&#x02014;again due to lack of awareness or lack of resources. Thus,&#x000a0;the disease is underdiagnosed and underreported.&#x000a0;</p>
        <p>According to a US Centers for Disease Control and Prevention survey from 2011, more than 11% of the US population aged 6 or older were infected and had a positive immunoglobulin G for&#x000a0;<italic toggle="yes">T gondii.</italic><xref ref-type="bibr" rid="article-95334.r17">[17]</xref><xref ref-type="bibr" rid="article-95334.r18">[18]</xref>&#x000a0;Some risk factors for seropositivity for <italic toggle="yes">T gondii</italic> included male sex, older age, persons without a high school diploma living in crowded conditions, and those living below the poverty level.<xref ref-type="bibr" rid="article-95334.r18">[18]</xref>&#x000a0;Among women of reproductive age, a decrease in&#x000a0;seroprevalence from 9.1% to 7.5% was seen from 2011 to 2014, but this was without statistical significance.<xref ref-type="bibr" rid="article-95334.r18">[18]</xref>&#x000a0;</p>
        <p><italic toggle="yes">T gondii</italic> infection&#x000a0;is estimated to have an average global seroprevalence rate of 25.7% (95% confidence interval 25.6%-25.8%). The overall range of seroprevalence was determined to be 0.5% to 87.7%. African countries had the highest average seroprevalence rate of 61.4%, followed by Oceania at 38.5%, South America at 31.2%, Europe at 29.6%, the US and Canada at 17.5%, and Asia at 16.4%.<xref ref-type="bibr" rid="article-95334.r19">[19]</xref>&#x000a0;The prevalence of infection varies both between countries and locally within a country. Differences in prevalence can be due to many factors. Some factors that increase the prevalence in certain areas include the higher seroprevalence of <italic toggle="yes">T&#x000a0;gondii</italic>&#x000a0;in warm and humid areas since oocysts survive better in these environments and also that areas with more livestock can be a direct source of infection and a possible reservoir for <italic toggle="yes">T gondii</italic>.<xref ref-type="bibr" rid="article-95334.r20">[20]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-95334.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p><italic toggle="yes">T gondii</italic> can overcome the host defenses and disseminate through the body to the liver and spleen, eluding the immune system and reaching the central nervous system by crossing the highly regulated blood-brain barrier and infecting the brain, where the parasite resides. Although most infections with <italic toggle="yes">T gondii</italic> are subclinical, a small percentage of immunocompetent people can develop acute toxoplasmosis that can manifest with nonspecific, constitutional symptoms, including fever, malaise, and lymphadenopathy, as well as central nervous system pathology and&#x000a0;ocular disease&#x02014;usually posterior uveitis.<xref ref-type="bibr" rid="article-95334.r3">[3]</xref>&#x000a0;After the initial infection,&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;becomes latent and persists for life; the latent tissue cysts can reactivate in profoundly immunosuppressed people, and reactivation can also occur during transplantation from the donor organ.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref>&#x000a0;</p>
        <p>Intracellular growth of tachyzoites results in direct cytopathic effects, cellular inflammation, and necrosis. Type 1 cell-mediated immunity is required to control acute and chronic infection of <italic toggle="yes">T gondii. </italic>Thus, any defects in cell-mediated immunity predispose the host to&#x000a0;severe manifestations of toxoplasmosis.<xref ref-type="bibr" rid="article-95334.r21">[21]</xref> In response to the damage caused by tachyzoite entry, the gastrointestinal epithelial cells produce chemokines&#x000a0;that act as chemical messengers, resulting in the recruitment of dendritic cells, macrophages, and neutrophils to the site of damage. The entry of tachyzoites into these inflammatory cells stimulates the production of interleukin-12 that induces interferon-&#x003b3; (IFN-&#x003b3;) synthesis by natural killer cells and T lymphocytes.<xref ref-type="bibr" rid="article-95334.r21">[21]</xref></p>
        <p>Synthesis of IFN-&#x003b3; is required to control acute and chronic infection. Low CD4 lymphocyte counts in patients with AIDS lead to reduced IFN-&#x003b3; levels, allowing unchecked multiplication of tachyzoites in acute infection and reactivation of bradyzoites in latent infection. This results in severe disease, manifesting as cerebral and extracerebral toxoplasmosis. Though cell-mediated immunity plays a crucial role in controlling the <italic toggle="yes">T gondii</italic> infection, humoral immunity&#x000a0;also contributes by synthesizing antibodies, modulating CD4 and CD8 T-cell responses, and amplifying IFN-&#x003b3; production.<xref ref-type="bibr" rid="article-95334.r22">[22]</xref></p>
      </sec>
      <sec id="article-95334.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Patients with toxoplasmosis often present with cervical and generalized lymphadenopathy, cerebral encephalitis, and ocular toxoplasmosis.&#x000a0;<italic toggle="yes">T gondii</italic> can be visualized during histopathological examination as either&#x000a0;tachyzoites or cysts. Tachyzoites look like crescents and are pathognomonic for acute disease. When cysts are visualized, they usually represent reactivation disease or latent infection.<xref ref-type="bibr" rid="article-95334.r23">[23]</xref><xref ref-type="bibr" rid="article-95334.r24">[24]</xref>&#x000a0;Usual stains such as hematoxylin and eosin, Wright, or Giemsa can be applied to tissue samples from blood, brain, sputum, centrifuged cerebrospinal fluid, or amniotic fluid. Hematoxylin and eosin tissue staining demonstrate&#x000a0;<italic toggle="yes">T gondii</italic> parasites (either in the form of tachyzoites or tissue cysts) in healthy and necrotic areas. If these findings are&#x000a0;observed&#x000a0;near blood vessels,&#x000a0;this may indicate hematogenous dissemination of <italic toggle="yes">T gondii</italic>.<xref ref-type="bibr" rid="article-95334.r25">[25]</xref>&#x000a0;Histological staining for diagnosing <italic toggle="yes">T gondii</italic> is not well-established, but it is suggested that this staining should be used in combination with other methodologies for diagnostic reasons.&#x000a0;</p>
        <p>The histological findings of biopsies of commonly involved organs are:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lymph node biopsy:</bold>&#x000a0;Parasites are rarely seen on the tissue specimen, but the triad of follicular hyperplasia, microgranulomas, and monocytoid B-cell hyperplasia are highly specific to <italic toggle="yes">T gondii</italic> infection.<xref ref-type="bibr" rid="article-95334.r23">[23]</xref><xref ref-type="bibr" rid="article-95334.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Brain biopsy:</bold>&#x000a0;Histology usually reveals necrotic areas with patchy diffuse encephalitis, cyst-containing lesions, microglial nodules, granulomas, and lymphocytic vasculitis.<xref ref-type="bibr" rid="article-95334.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Ocular biopsy:</bold>&#x000a0;This is characterized by necrosis in segmental panophthalmitis with associated tissue cysts and tachyzoites.<xref ref-type="bibr" rid="article-95334.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-95334.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Obtaining a complete history of the present illness and exposure history is paramount in all patients because exposure histories are essential to increasing the clinician's index of suspicion and leading to the correct diagnosis. Most immunocompetent individuals infected with <italic toggle="yes">T gondii</italic> are asymptomatic; the&#x000a0;<italic toggle="yes">T gondii </italic>then&#x000a0;remains in the body and becomes latent. However, some immunocompetent individuals with primary, acute infection may complain of nonspecific constitutional symptoms, including fevers, chills, headaches, pharyngitis, myalgias, rash, and nontender cervical lymphadenopathy. More rarely, those who are immunocompetent have been reported to have hepatitis and myocarditis.<xref ref-type="bibr" rid="article-95334.r3">[3]</xref><xref ref-type="bibr" rid="article-95334.r28">[28]</xref><xref ref-type="bibr" rid="article-95334.r29">[29]</xref><xref ref-type="bibr" rid="article-95334.r30">[30]</xref></p>
        <p>A complete exposure history is essential; inquiries about exposure to cat feces are mandatory. However, since&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;is also present in the environment and can be acquired from environmental and food sources,&#x000a0;narrowing exposure and infection down to only cats&#x000a0;could&#x000a0;miss certain cases. Always considering toxoplasmosis in the differential diagnosis of any patient who presents with fevers and cervical lymphadenopathy, whether they have had an exposure history that is compatible with toxoplasmosis is important.<xref ref-type="bibr" rid="article-95334.r31">[31]</xref>&#x000a0;</p>
        <p>In immunosuppressed individuals, such as patients with HIV/AIDS and those who have received a solid organ or hematopoietic cell transplantation, toxoplasmosis can reactivate and present as an opportunistic infection. Patients can&#x000a0;develop&#x000a0;symptoms and signs of encephalitis, myocarditis, hepatosplenomegaly, retinochoroiditis, and pneumonitis.<xref ref-type="bibr" rid="article-95334.r32">[32]</xref>&#x000a0;In patients with HIV/AIDS, the parasite can reactivate and cause disease, usually when the CD4 lymphocyte count falls below 100 cells/&#x003bc;L; the risk of reactivation in these individuals can be as high as 30% if they are seropositive for <italic toggle="yes">T gondii</italic> and are not taking prophylactic treatment.<xref ref-type="bibr" rid="article-95334.r33">[33]</xref></p>
        <p>The most common presentation of <italic toggle="yes">T gondii</italic> reactivation disease in patients with HIV/AIDS with CD4 lymphocyte counts less than 100 cells/&#x003bc;L is signs and symptoms of central nervous system disease from toxoplasmic encephalitis. Cerebral toxoplasmosis usually presents with neurological symptoms based on the region of the brain involved and the number of lesions. Symptoms may include fevers, seizures, headaches, changes in vision, altered mental status, focal neurological deficits, cognitive dysfunction, ataxia, involuntary movements, and stupor and coma.<xref ref-type="bibr" rid="article-95334.r13">[13]</xref>&#x000a0;Cerebrospinal fluid analysis may demonstrate nonspecific findings, such as mild protein elevation and monocytosis. Extracerebral disease can also occur, typically as pneumonitis and chorioretinitis, although cardiac, gastrointestinal, genitourinary, musculoskeletal, and disseminated diseases can also occur. Pneumonitis can present with fever, cough, and shortness of breath. Chorioretinitis commonly presents with visual changes, floaters, or ocular pain.<xref ref-type="bibr" rid="article-95334.r34">[34]</xref><xref ref-type="bibr" rid="article-95334.r35">[35]</xref></p>
      </sec>
      <sec id="article-95334.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of toxoplasmosis may be challenging in immunocompetent and immunosuppressed individuals. The diagnosis may be missed in immunocompetent people with few nonspecific symptoms due to a lack of clinical suspicion. The diagnosis can be made indirectly with serological testing for IgM and IgG. Serologic testing alone is not diagnostic in immunosuppressed people with central nervous system lesions. First, immunosuppressed individuals may not mount an immune response to make antibodies, and anti-toxoplasmosis IgG is prevalent in the general population. Hence, a more definitive diagnostic approach is necessary.</p>
        <p>Biopsy of the affected organ provides a definite diagnosis, but this may not always be possible. Those who are immunosuppressed with central nervous system disease will usually need to have more than a single finding and also have symptoms compatible with the disease, computed tomography (CT) or magnetic resonance imaging (MRI) evidence of multiple, hypodense, ring-enhancing focal lesions in the cortex and periventricular areas, primarily in the basal ganglia, thalami, and corticomedullary junction,&#x000a0;and detection of toxoplasma deoxyribonucleic acid (DNA) in cerebrospinal fluid or the presence of the organism in a biopsy specimen.<xref ref-type="bibr" rid="article-95334.r15">[15]</xref></p>
        <p>Although a biopsy of the affected organ provides a definitive diagnosis, toxoplasmosis can also be diagnosed using noninvasive testing, including labs and imaging.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Serological testing:</bold>&#x000a0;This is the primary diagnostic method for determining&#x000a0;infection with <italic toggle="yes">T&#x000a0;gondii</italic>&#x000a0;by identifying IgM and IgG antibodies using enzyme-linked immunosorbent assays. IgM antibodies are usually detectable from day 5 following infection, reaching maximum levels in 1&#x000a0;to 2 months. IgG antibodies are detectable after 1&#x000a0;to 2 weeks of infection, reaching maximum levels in 3&#x000a0;to 6 months.&#x000a0;<italic toggle="yes">T gondii</italic> IgM antibody testing lacks specificity. Immunosuppressed individuals may not be able to mount an appropriate immune response, and therefore, serologies may not be helpful in the diagnosis of these patients.<xref ref-type="bibr" rid="article-95334.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Molecular testing:</bold>&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;DNA can be detected by polymerase chain reaction (PCR) from blood and other bodily fluids to diagnose primary, reactivation, or latent infection, especially in those who are severely immunosuppressed. Although PCR is not routinely&#x000a0;performed on immunocompetent individuals with fever and lymphadenopathy, it can be&#x000a0;helpful for the diagnosis of <italic toggle="yes">T gondii</italic> in those who are immunocompromised. There is no standardized PCR for toxoplasmosis; the test remains helpful for diagnosing immunocompromised hosts with suspected central nervous system, pulmonary, or disseminated disease.<xref ref-type="bibr" rid="article-95334.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Radiological diagnosis:</bold>&#x000a0;CT or MRI of the brain will typically reveal multiple, hypodense, ring-enhancing focal lesions in the cortex and periventricular areas, primarily in the basal ganglia, thalami, and corticomedullary junction.<xref ref-type="bibr" rid="article-95334.r15">[15]</xref>&#x000a0;An &#x0201c;eccentric target sign&#x0201d; may be present, consistent with an eccentric nodule along the rim of an enhancing lesion. This is considered pathognomonic.<xref ref-type="bibr" rid="article-95334.r15">[15]</xref> Minimal inflammatory changes seen during the early stages may not be appreciated well on CT; MRI is preferred for diagnosing brain lesions in cerebral toxoplasmosis. Single-photon emission CT or positron emission tomography scans have high specificity to rule out differential diagnoses.</p>
          </list-item>
          <list-item>
            <p><bold>Biopsy:&#x000a0;</bold>Although this provides a definitive diagnosis by demonstrating tachyzoites and tissue cysts of&#x000a0;<italic toggle="yes">T gondii</italic>, it&#x000a0;is not usually performed. A biopsy is indicated to rule out other differential diagnoses in individuals failing to show clinical or radiological improvement of symptoms within 14 days of starting the therapy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-95334.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The main goal of treatment&#x000a0;is to limit parasite multiplication during active infection. Prophylaxis with trimethoprim-sulfamethoxazole&#x000a0;can prevent acute infection in those who are immunosuppressed and should be considered in patients who need it according to local or international guidelines.<xref ref-type="bibr" rid="article-95334.r16">[16]</xref><xref ref-type="bibr" rid="article-95334.r37">[37]</xref><xref ref-type="bibr" rid="article-95334.r38">[38]</xref>&#x000a0;Treatment is indicated in immunocompetent individuals with severe or prolonged symptoms and all those who are immunocompromised.</p>
        <p>In immunosuppressed individuals, it is essential to ascertain which patients need prophylactic medication to avoid reactivation of toxoplasmosis.&#x000a0;Reactivation of latent cysts is the primary mechanism of toxoplasmosis following HSCT and SOT and when patients with HIV/AIDS have a CD4 lymphocyte count of less than 100 cells/&#x003bc;L. The preferred regimen for prophylaxis in these patients is trimethoprim-sulfamethoxazole.<xref ref-type="bibr" rid="article-95334.r16">[16]</xref><xref ref-type="bibr" rid="article-95334.r38">[38]</xref>&#x000a0;Early diagnosis of toxoplasmosis and initiation of empiric treatment, as well as antiretroviral therapy in patients with HIV/AIDS,&#x000a0;improves outcomes in immunosuppressed individuals.<xref ref-type="bibr" rid="article-95334.r38">[38]</xref>&#x000a0;</p>
        <p>In patients who have received HSCT and SOT, toxoplasmosis is associated with high mortality.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref>&#x000a0;Patients&#x000a0;who are most likely to develop reactivation of toxoplasmosis are those&#x000a0;who were seropositive before transplantation, especially those who do not receive chemoprophylaxis with trimethoprim-sulfamethoxazole.<xref ref-type="bibr" rid="article-95334.r16">[16]</xref>&#x000a0;Targeted chemoprophylaxis improved outcomes for SOT recipients.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref>&#x000a0;Prophylactic therapy with trimethoprim-sulfamethoxazole may be indicated depending on patients' immune status and serological or PCR positivity. Decisions for initiating prophylactic regiments in patients undergoing HSCT and SOT who are seropositive for&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;and who may not be able to tolerate prophylactic regimens may be screened by using quantitative PCR to determine whether there is active infection early as a pre-emptive strategy to initiate treatment.<xref ref-type="bibr" rid="article-95334.r16">[16]</xref></p>
        <p>In cases of suspected <italic toggle="yes">T gondii</italic> infection, empirical therapy based on presumptive diagnosis is preferred rather than waiting for test results. The combination of pyrimethamine (200 mg loading dose followed by 50 mg daily for patients weighing less than 60 kg and 75 mg daily for patients who weigh more than 60 kg) and sulfadiazine (1000 mg 4 times a day for patients who weigh less than 60 kg and 1500 mg 4 times a day for patients who weigh more than 60 kg) is the preferred regimen for treatment. An alternative treatment can be trimethoprim-sulfamethoxazole. Initial therapy&#x000a0;should be continued for 6 weeks and be followed by chronic maintenance therapy.<xref ref-type="bibr" rid="article-95334.r39">[39]</xref>&#x000a0;Folic acid is usually added to the treatment regimen to prevent folic acid deficiency because sulfadiazine&#x000a0;inhibits folic acid biosynthesis. In central nervous system and ocular toxoplasmosis, steroids&#x000a0;can be added to the standard regimen to treat cerebral edema&#x000a0;and ocular toxoplasmosis.<xref ref-type="bibr" rid="article-95334.r40">[40]</xref><xref ref-type="bibr" rid="article-95334.r41">[41]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-95334.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for toxoplasmosis may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system lymphoma</p>
          </list-item>
          <list-item>
            <p>Metastatic brain lesions</p>
          </list-item>
          <list-item>
            <p>Progressive multifocal encephalopathy</p>
          </list-item>
          <list-item>
            <p>Cerebral tuberculosis</p>
          </list-item>
          <list-item>
            <p>Bacterial or fungal brain abscess&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cytomegalovirus</p>
          </list-item>
          <list-item>
            <p>Acute HIV infection</p>
          </list-item>
          <list-item>
            <p>Herpes simplex encephalitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-95334.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis and outcomes of toxoplasmosis in patients vary and depend on factors such as their immune competence and the location of the reactivation. Acute toxoplasmosis is typically self-limited in immunocompetent individuals. The prognosis is excellent without any long-term effects of infection. Early diagnosis of toxoplasmosis and initiation of empiric treatment, as well as antiretroviral therapy in patients with HIV/AIDS,&#x000a0;improves outcomes in immunosuppressed individuals.</p>
        <p>Prophylactic treatment is indicated in all patients with HIV/AIDS with CD4 lymphocyte counts less than 100 cells/&#x003bc;L with trimethoprim-sulfamethoxazole. Toxoplasmosis is associated with high mortality in patients who have received HSCT and SOT.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref>&#x000a0;Targeted chemoprophylaxis improved outcomes for SOT recipients.<xref ref-type="bibr" rid="article-95334.r4">[4]</xref>&#x000a0;Further, depending on patients' immune status and serological or PCR positivity, prophylactic therapy with trimethoprim-sulfamethoxazole may be indicated.</p>
      </sec>
      <sec id="article-95334.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Toxoplasmosis can cause severe life-threatening complications in immunosuppressed individuals, manifesting as toxoplasmic encephalitis or extracerebral toxoplasmosis. Initiation of treatment can be complicated by immune reconstitution inflammatory syndrome, resulting in a paradoxical worsening of symptoms. Treatment involves continuing anti-infective therapy, antiretroviral therapy, and starting steroids (or increasing the dose if patients are already on steroids).</p>
      </sec>
      <sec id="article-95334.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Immunocompetent individuals diagnosed with toxoplasmosis would benefit from the consultation of an infectious disease clinician and other healthcare professionals who specialize in the affected organs, eg, an ophthalmologist for chorioretinitis. Infectious disease clinicians should follow immunosuppressed patients&#x000a0;for the prevention of toxoplasmosis and for the diagnosis, treatment, and follow-up of these patients.</p>
      </sec>
      <sec id="article-95334.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Infection with&#x000a0;<italic toggle="yes">T gondii</italic>&#x000a0;is very high in some parts of the world. Although primary infections can be self-limiting, there is a risk for more severe disease with reactivation of latent infection. Patients can reduce their risk of being infected by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cooking food to safe temperatures or freezing meats for several days at sub-zero temperatures before cooking</p>
          </list-item>
          <list-item>
            <p>Thoroughly washing or peeling all fruits and vegetables</p>
          </list-item>
          <list-item>
            <p>Thoroughly washing surfaces that have come in contact with raw meat, poultry, seafood, and unwashed fruits or vegetables</p>
          </list-item>
          <list-item>
            <p>Avoiding unpasteurized goat milk</p>
          </list-item>
          <list-item>
            <p>Wearing gloves and performing appropriate hand hygiene after touching cat litter boxes or any sand or soil that may have been in contact with cat feces</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-95334.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Global efforts to reduce the burden of <italic toggle="yes">T gondii</italic> in the environment and the food chain are required to prevent primary infection.</p>
      </sec>
      <sec id="article-95334.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team approach in evaluating patients for toxoplasmosis can aid in early diagnosis and treatment. Given the high incidence of worldwide infection, increasing awareness of the disease and its manifestations is necessary, especially when immunocompetent individuals have symptoms, as it can be underdiagnosed.<xref ref-type="bibr" rid="article-95334.r31">[31]</xref>&#x000a0;Efforts to raise awareness of the diagnosis of primary infection can help prevent individuals from being at risk of developing severe diseases during their lifetime. Additionally, increased awareness and education regarding prophylaxis therapy can help reduce the incidence of reactivation of latent infection.</p>
      </sec>
      <sec id="article-95334.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=95334&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=95334">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/toxoplasmosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=95334">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/95334/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=95334">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-95334.s18">
        <title>References</title>
        <ref id="article-95334.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>VanWormer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>More people, more cats, more parasites: Human population density and temperature variation predict prevalence of Toxoplasma gondii oocyst shedding in free-ranging domestic and wild felids.</article-title>
            <source>PLoS One</source>
            <year>2023</year>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>e0286808</fpage>
            <pub-id pub-id-type="pmid">37343040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adekunle</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spicer</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Steinbrink</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Phadke</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Woodworth</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers.</article-title>
            <source>Transpl Infect Dis</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>e13636</fpage>
            <pub-id pub-id-type="pmid">33993599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Layton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Theiopoulou</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Rutenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elshereye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sinnott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Contopoulos-Ioannidis</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Clinical Spectrum, Radiological Findings, and Outcomes of Severe Toxoplasmosis in Immunocompetent Hosts: A Systematic Review.</article-title>
            <source>Pathogens</source>
            <year>2023</year>
            <month>Mar</month>
            <day>31</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">37111429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert-Gangneux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meroni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Botterel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>JMA</given-names>
              </name>
              <name>
                <surname>Brenier-Pinchart</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Accoceberry</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Akan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abbate</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boggian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bruschi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carratal&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drgona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Djurkovi&#x00107;-Djakovi&#x00107;</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Farinas</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Genco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gkrania-Klotsas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Groll</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hirzel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kurt</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Junie</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lazzarotto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Len</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pana</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Roilides</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stajner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Delden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Villena</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pelloux</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Manuel</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis in Transplant Recipients, Europe, 2010-2014.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>1497</fpage>
            <page-range>1497-1504</page-range>
            <pub-id pub-id-type="pmid">30014843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rauwolf</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Floeth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kerl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schaumburg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Groll</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis after allogeneic haematopoietic cell transplantation-disease burden and approaches to diagnosis, prevention and management in adults and children.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>378</fpage>
            <page-range>378-388</page-range>
            <pub-id pub-id-type="pmid">33065238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Attias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Benchimol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vommaro</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Crepaldi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>De Souza</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The life-cycle of Toxoplasma gondii reviewed using animations.</article-title>
            <source>Parasit Vectors</source>
            <year>2020</year>
            <month>Nov</month>
            <day>23</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>588</fpage>
            <pub-id pub-id-type="pmid">33228743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gering</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laubach</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>PSD</given-names>
              </name>
              <name>
                <surname>Soboll Hussey</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>KDS</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Perng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pioon</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Holekamp</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Getty</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasma gondii infections are associated with costly boldness toward felids in a wild host.</article-title>
            <source>Nat Commun</source>
            <year>2021</year>
            <month>Jun</month>
            <day>22</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>3842</fpage>
            <pub-id pub-id-type="pmid">34158487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmore</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention.</article-title>
            <source>Trends Parasitol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>190</fpage>
            <page-range>190-6</page-range>
            <pub-id pub-id-type="pmid">20202907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubey</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Speer</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>267</fpage>
            <page-range>267-99</page-range>
            <pub-id pub-id-type="pmid">9564564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tenter</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Heckeroth</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasma gondii: from animals to humans.</article-title>
            <source>Int J Parasitol</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>12-13</issue>
            <fpage>1217</fpage>
            <page-range>1217-58</page-range>
            <pub-id pub-id-type="pmid">11113252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sibley</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ajioka</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Genetic diversity of Toxoplasma gondii in animals and humans.</article-title>
            <source>Philos Trans R Soc Lond B Biol Sci</source>
            <year>2009</year>
            <month>Sep</month>
            <day>27</day>
            <volume>364</volume>
            <issue>1530</issue>
            <fpage>2749</fpage>
            <page-range>2749-61</page-range>
            <pub-id pub-id-type="pmid">19687043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batz</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Ranking the disease burden of 14 pathogens in food sources in the United States using attribution data from outbreak investigations and expert elicitation.</article-title>
            <source>J Food Prot</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>75</volume>
            <issue>7</issue>
            <fpage>1278</fpage>
            <page-range>1278-91</page-range>
            <pub-id pub-id-type="pmid">22980012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidal</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease.</article-title>
            <source>J Int Assoc Provid AIDS Care</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>18</volume>
            <fpage>2325958219867315</fpage>
            <pub-id pub-id-type="pmid">31429353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aguirre</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Longcore</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dabritz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Lepczyk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lilly</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Milcarsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>VanWormer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yolken</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sizemore</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies.</article-title>
            <source>Ecohealth</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>378</fpage>
            <page-range>378-390</page-range>
            <pub-id pub-id-type="pmid">30945159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elsheikha</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>XQ</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2021</year>
            <month>Mar</month>
            <day>17</day>
            <volume>34</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33239310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aerts</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Groll</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lagrou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perruccio</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blijlevens</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bretagne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cordonnier</surname>
                <given-names>C</given-names>
              </name>
              <collab>European Conference on Infections in Leukaemia group</collab>
            </person-group>
            <article-title>Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2024</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>e291</fpage>
            <page-range>e291-e306</page-range>
            <pub-id pub-id-type="pmid">38134949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kruszon-Moran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sanders-Lewis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>405</fpage>
            <page-range>405-10</page-range>
            <pub-id pub-id-type="pmid">17827351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kruszon-Moran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Press</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>McQuillan</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title><italic>Toxoplasma gondii</italic> Infection in the United States, 2011-2014.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>551</fpage>
            <page-range>551-557</page-range>
            <pub-id pub-id-type="pmid">29260660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nosaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots.</article-title>
            <source>Trop Biomed</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>898</fpage>
            <page-range>898-925</page-range>
            <pub-id pub-id-type="pmid">33597463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stelzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Benavides Silv&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ortega-Mora</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Maksimov</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gethmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Conraths</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Schares</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title><italic>Toxoplasma gondii</italic> infection and toxoplasmosis in farm animals: Risk factors and economic impact.</article-title>
            <source>Food Waterborne Parasitol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>15</volume>
            <fpage>e00037</fpage>
            <pub-id pub-id-type="pmid">32095611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Akbar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gomez-Marin</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dimier-Poisson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Immune response against toxoplasmosis-some recent updates RH: <italic>Toxoplasma gondii</italic> immune response.</article-title>
            <source>Int J Immunopathol Pharmacol</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>36</volume>
            <fpage>3946320221078436</fpage>
            <pub-id pub-id-type="pmid">35227108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halonen</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2013</year>
            <volume>114</volume>
            <fpage>125</fpage>
            <page-range>125-45</page-range>
            <pub-id pub-id-type="pmid">23829904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eapen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Aravindan</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Evidence based criteria for the histopathological diagnosis of toxoplasmic lymphadenopathy.</article-title>
            <source>J Clin Pathol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>58</volume>
            <issue>11</issue>
            <fpage>1143</fpage>
            <page-range>1143-6</page-range>
            <pub-id pub-id-type="pmid">16254101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Liesenfeld</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis.</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>Jun</month>
            <day>12</day>
            <volume>363</volume>
            <issue>9425</issue>
            <fpage>1965</fpage>
            <page-range>1965-76</page-range>
            <pub-id pub-id-type="pmid">15194258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Furtado</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Winthrop</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Ocular toxoplasmosis II: clinical features, pathology and management.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <page-range>95-108</page-range>
            <pub-id pub-id-type="pmid">22712598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Luca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Lisio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lattanzio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Antuono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liberatore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aiello</surname>
                <given-names>FB</given-names>
              </name>
            </person-group>
            <article-title>First case report of M1 macrophage polarization in an untreated symptomatic patient with toxoplasmosis.</article-title>
            <source>BMC Infect Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <day>27</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <pub-id pub-id-type="pmid">29580227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chimelli</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A morphological approach to the diagnosis of protozoal infections of the central nervous system.</article-title>
            <source>Patholog Res Int</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>290853</fpage>
            <pub-id pub-id-type="pmid">21785681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCabe</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Dorfman</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy.</article-title>
            <source>Rev Infect Dis</source>
            <year>1987</year>
            <season>Jul-Aug</season>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>754</fpage>
            <page-range>754-74</page-range>
            <pub-id pub-id-type="pmid">3326123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelwan</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Shakinah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clarissa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hosea</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Herdanto</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Pandelaki</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Rare cardiac complication of toxoplasmosis in immunocompetent host.</article-title>
            <source>IDCases</source>
            <year>2022</year>
            <volume>29</volume>
            <fpage>e01533</fpage>
            <pub-id pub-id-type="pmid">35756700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pazoki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ziaee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anvari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rezaei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ahmadpour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haghparast-Kenari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saljoghi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Biderouni</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Barac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pagheh</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasma gondii infection as a potential risk for chronic liver diseases: A systematic review and meta-analysis.</article-title>
            <source>Microb Pathog</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>149</volume>
            <fpage>104578</fpage>
            <pub-id pub-id-type="pmid">33069795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Harari</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>High burden and low awareness of toxoplasmosis in the United States.</article-title>
            <source>Postgrad Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>131</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-108</page-range>
            <pub-id pub-id-type="pmid">30638425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ganiem</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ekawardhani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cerebral toxoplasmosis in HIV-infected patients: a review.</article-title>
            <source>Pathog Glob Health</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-23</page-range>
            <pub-id pub-id-type="pmid">35694771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Ingole</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Seroprevalence of <italic>Toxoplasma gondii</italic> in newly diagnosed HIV seropositive patients.</article-title>
            <source>Indian J Med Res</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>152</volume>
            <issue>5</issue>
            <fpage>515</fpage>
            <page-range>515-518</page-range>
            <pub-id pub-id-type="pmid">33707394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Imoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Norose</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hikosaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurahashi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acute exacerbation of pulmonary toxoplasmosis during corticosteroid therapy for immune thrombocytopenia: A case report and literature review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2021</year>
            <month>Dec</month>
            <day>23</day>
            <volume>100</volume>
            <issue>51</issue>
            <fpage>e28430</fpage>
            <pub-id pub-id-type="pmid">34941194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crosson</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kuthyar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shantha</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Debiec</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Laird</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Grossniklaus</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis chorioretinitis mimicking acute retinal necrosis associated with local corticosteroid.</article-title>
            <source>Int J Retina Vitreous</source>
            <year>2020</year>
            <volume>6</volume>
            <fpage>21</fpage>
            <pub-id pub-id-type="pmid">32514378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guitard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brenier-Pinchart</surname>
                <given-names>M-P</given-names>
              </name>
              <name>
                <surname>Varlet-Marie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rouges</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Argy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bonhomme</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Capitaine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gu&#x000e9;gan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>R-A</given-names>
              </name>
              <name>
                <surname>Dard&#x000e9;</surname>
                <given-names>M-L</given-names>
              </name>
              <name>
                <surname>Pelloux</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Robert-Gangneux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yera</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sterkers</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Multicenter evaluation of the <italic>Toxoplasma gondii</italic> Real-TM (Sacace) kit performance for the molecular diagnosis of toxoplasmosis.</article-title>
            <source>J Clin Microbiol</source>
            <year>2024</year>
            <month>Apr</month>
            <day>10</day>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>e0142823</fpage>
            <pub-id pub-id-type="pmid">38470023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajapakse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weeratunga</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Silva</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Fernando</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis of human toxoplasmosis: a systematic review.</article-title>
            <source>Pathog Glob Health</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>111</volume>
            <issue>7</issue>
            <fpage>333</fpage>
            <page-range>333-342</page-range>
            <pub-id pub-id-type="pmid">28948861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambrosioni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alagaratnam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Bremen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mastrangelo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waalewijn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Guaraldi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boesecke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cinque</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bamford</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calmy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marzolini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oprea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koval</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mendao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rockstroh</surname>
                <given-names>JK</given-names>
              </name>
              <collab>EACS Governing Board</collab>
            </person-group>
            <article-title>Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.</article-title>
            <source>HIV Med</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>1126</fpage>
            <page-range>1126-1136</page-range>
            <pub-id pub-id-type="pmid">37849432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pau</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <collab>National Institutes of Health</collab>
              <collab>Centers for Disease Control and Prevention</collab>
              <collab>HIV Medicine Association of the Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>May</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>1308</fpage>
            <page-range>1308-11</page-range>
            <pub-id pub-id-type="pmid">24585567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zoubi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zulfiqar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cerebral toxoplasmosis requiring urgent brain biopsy.</article-title>
            <source>IDCases</source>
            <year>2017</year>
            <volume>9</volume>
            <fpage>59</fpage>
            <page-range>59-61</page-range>
            <pub-id pub-id-type="pmid">28702359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-95334.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holland</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>An update on current practices in the management of ocular toxoplasmosis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-14</page-range>
            <pub-id pub-id-type="pmid">12095816</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
